Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma

ClinicalTrials.gov ID: NCT00992173

Public ClinicalTrials.gov record NCT00992173. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma

Study identification

NCT ID: NCT00992173
Recruitment status: Withdrawn
Study type: Interventional
Phase: Phase 2
Lead sponsor: Molecular Insight Pharmaceuticals, Inc.; Industry
Enrollment: Not listed

Conditions and interventions

Conditions

Neuroblastoma

Interventions

Ultratrace Iobenguane I 131 Drug

Drug

Eligibility (public fields only)

Age range: 12 Months and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 31, 2009
Primary completion: Sep 30, 2011
Completion: Not listed
Last update posted: Nov 25, 2015

Started 2010

United States locations

U.S. sites: 20
U.S. states: 14
U.S. cities: 16

Facility	City	State	ZIP	Site status
Children's Hospital of LA	Los Angeles	California	90027	—
UCSF Pediatric Hematology/Oncology	San Francisco	California	94143	—
University of Miami Miller School of Medicine	Miami	Florida	33136	—
Childrens Memorial/Northwestern University	Chicago	Illinois	60614	—
Comer's Childrens Hospital/University of Chicago	Chicago	Illinois	60637	—
University of iowa	Iowa City	Iowa	52242	—
Johns Hopkins University	Baltimore	Maryland	21287	—
Children's Hospital/Dana Farber Cancer Institute	Boston	Massachusetts	02115	—
CS Motts Children's Hospital	Ann Arbor	Michigan	48105	—
Mount Sinai School of Medicine	New York	New York	10029	—
Hospital - Weill Cornell Medical Center	New York	New York	10032	—
Memorial Sloan Kettering	New York	New York	10065	—
Duke University Medical Center	Durham	North Carolina	27710	—
Cincinnati Children's Hospital	Cincinnati	Ohio	45229	—
Children's Hospital of Philadelphia	Philadelphia	Pennsylvania	19104	—
Medical University of South Carolina	Charleston	South Carolina	29425	—
Cook Children's Healthcare System	Fort Worth	Texas	76104	—
MD Anderson Cancer Center	Houston	Texas	77030	—
Texas Childrens Hospital Cancer Center	Houston	Texas	77030	—
University of Wisconsin Medical Center	Madison	Wisconsin	53792	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00992173, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 25, 2015 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00992173 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →